Date:	--/--/-- --:--:--
Event Id:	E5DP283ER
Action Type:	ACQUISITION
Action Status:	REJECTED
Acquirer Symbol:
Target Symbol:	MTSR
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	62.2
Price Per Share Currency:	USD
News References:	https://www.prnewswire.com/news-releases/pfizer-and-metsera-enter-into-merger-agreement-amendment-metseras-board-of-directors-reaffirms-support-of-merger-with-pfizer-302609256.html

Action Notes

Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera). Under the terms of the proposal, Novo Nordisk would acquire all outstanding shares of Metsera's common stock at a price of 56.50 USD per share in cash (equal to an approximate aggregated equity value of 6.5 billion USD or approximate enterprise value of 6.0 billion USD) and contingent value rights (CVRs) for up to 21.25 USD per share in cash (or an approximate aggregated value of up to 2.5 billion USD) based on the achievement of certain clinical and regulatory milestones. The cash consideration will be paid at signing in exchange for non-voting preferred stock representing 50% of Metsera's share capital and the CVRs will be issued upon the closing of the acquisition in exchange for the remaining shares. The proposal is currently subject to review by the Metsera board of directors.